SCHEMBL697363

SCHEMBL697363

Cc1ccc(C(=O)O)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.65
HPGD P15428 1/20 0.53
SRD5A2 P31213 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
CHRNA1 P02708 1/20 0.51
CHRNG P07510 1/20 0.51
CHRNB1 P11230 1/20 0.51
CHRNB2 P17787 1/20 0.51
SLC6A2 P23975 1/20 0.51
CHRNB4 P30926 1/20 0.51
SLC6A4 P31645 1/20 0.51
CHRNA3 P32297 1/20 0.51
CHRNA4 P43681 1/20 0.51
SLC6A3 Q01959 1/20 0.51
CHRND Q07001 1/20 0.51
TTR P02766 1/20 0.50
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619400 1.00 TSHR (0.65) TSHRHPGDSRD5A2SMN1; SMN2CHRNA1
Hydrochloric Acid SCHEMBL14660193 0.98 TSHR (0.63) TSHRHPGDSRD5A2SMN1; SMN2CHRNA1
SCHEMBL2924706 0.84 HPGD (0.54) TSHRHPGDSRD5A2SMN1; SMN2CHRNA1
Terephthalic Acid SCHEMBL27403238 0.83 CYP3A4 (0.68) TSHRHPGDSRD5A2SMN1; SMN2ALDH1A1
SCHEMBL4546533 0.83 HPGD (0.53) TSHRHPGDSMN1; SMN2CHRNA1CHRNG
SCHEMBL703716 0.83 HPGD (0.53) HPGDSMN1; SMN2CHRNA1CHRNGCHRNB1
SCHEMBL703101 0.83 TSHR (0.65) TSHRSRD5A2SMN1; SMN2ALDH1A1MEN1
Methylpiperazine SCHEMBL27675357 0.82 HPGD (0.47) TSHRHPGDSMN1; SMN2SLC6A2SLC6A4
SCHEMBL10778405 0.81 HPGD (0.51) TSHRHPGDSMN1; SMN2CHRNA1CHRNG
Hydrogen Sulfide SCHEMBL28759691 0.81 TSHR (0.63) TSHRSRD5A2SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109212056-B Gas chromatography-mass spectrometry combined method for determining three trace monohalogenated methylbenzoic acids in water source water 丁立平 2021-05-07 CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP claimed
CN-108218708-B Preparation method and application of 5-chloro-4-methyl-2-nitrobenzoic acid 利尔化学股份有限公司 2021-01-05 CN claimed
EP-3551633-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 EP claimed
WO-2018108230-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2018-06-21 WO claimed
EP-1797186-B1 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE NAT RES COUNCIL CANADA (CA) 2016-05-25 EP claimed
US-8728759-B2 Reverse cumate repressor mutant NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2014-05-20 US claimed
US-8252556-B2 Reverse cumate repressor mutant NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2012-08-28 US claimed
US-20110171686-A1 REVERSE CUMATE REPRESSOR MUTANT NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2011-07-14 US claimed
US-20090176275-A1 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2009-07-09 US claimed
US-20080311618-A1 Expression System, Components Thereof and Methods of Use NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2008-12-18 US claimed
EP-1797186-A4 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE CA NAT RESEARCH COUNCIL (CA) 2008-11-12 EP claimed
EP-1797186-A1 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2007-06-20 EP claimed
WO-2006037215-A1 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2006-04-13 WO claimed
US-20040205834-A1 System for inducible expression in eukaryotic cells NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2004-10-14 US claimed
EP-1385946-A2 A SYSTEM FOR INDUCIBLE EXPRESSION IN EUKARYOTIC CELLS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2004-02-04 EP claimed
WO-2002088346-A2 A SYSTEM FOR INDUCIBLE EXPRESSION IN EUKARYOTIC CELLS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2002-11-07 WO claimed
US-12466816-B2 Fused cyclic compound capable of degrading protein and use thereof SHANGHAITECH UNIVERSITY (CN) 2025-11-11 US disclosed
US-3982931-A N,N-di-sec.butyl-benzamide herbicides MONTEDISON S.P.A. (IT) 1976-09-28 US disclosed
US-3952012-A MULTISTAGE MCNEIL LABORATORIES, INCORPORATED (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466816-B2 Fused cyclic compound capable of degrading protein and use thereof PSMD7, PSMD2, PSMA6 TSHR 4431/4885HPGD 1578/4885SRD5A2 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.